ATG/PTCy in Haplo-PBSCT Randomized Controlled,Multi-center

PHASE4CompletedINTERVENTIONAL
Enrollment

418

Participants

Timeline

Start Date

July 28, 2018

Primary Completion Date

August 23, 2023

Study Completion Date

August 23, 2023

Conditions
Myeloid Tumor
Interventions
DRUG

ATG/PTCy

low dose Antithymocyte Globulin plus low dose post-transplant cyclophosphamide as graft-versus-host disease prophylaxis in haploidentical peripheral blood stem cell transplantation

DRUG

standard ATG

in vivo T cell depletion (TCD) with anti-thymocyte globulin (ATG) as graft-versus-host disease prophylaxis in haploidentical peripheral blood stem cell transplantation

DRUG

standard PTCy

post-transplant cyclophosphamide (PTCy) as graft-versus-host disease prophylaxis in haploidentical peripheral blood stem cell

Trial Locations (6)

200002

Shanghai Ruijin Hospital, affiliated with the Medical School of Shanghai Jiaotong University,, Shanghai

200080

Changhai Hospital, Shanghai

Xianmin Song, Shanghai

Unknown

General Hospital of Jinan Military Command., Qinan

Shanghai Xinghua Hospital, affiliated with the Medical School of Shanghai Jiaotong University,, Shanghai

Shanghai tongji hospital, Shanghai

All Listed Sponsors
lead

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

OTHER

NCT03608059 - ATG/PTCy in Haplo-PBSCT Randomized Controlled,Multi-center | Biotech Hunter | Biotech Hunter